These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25691568)

  • 21. Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.
    Pflug A; Gaudon S; Resa-Infante P; Lethier M; Reich S; Schulze WM; Cusack S
    Nucleic Acids Res; 2018 Jan; 46(2):956-971. PubMed ID: 29202182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain.
    Pautus S; Sehr P; Lewis J; Fortuné A; Wolkerstorfer A; Szolar O; Guilligay D; Lunardi T; Décout JL; Cusack S
    J Med Chem; 2013 Nov; 56(21):8915-30. PubMed ID: 24134208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication.
    Huang Q; Zhong Y; Li J; Ye Y; Wu W; Chen L; Feng M; Yang J; Liu S
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1143-1149. PubMed ID: 32327257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue.
    Kuzuhara T; Kise D; Yoshida H; Horita T; Murazaki Y; Nishimura A; Echigo N; Utsunomiya H; Tsuge H
    J Biol Chem; 2009 Mar; 284(11):6855-60. PubMed ID: 19144639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure of a functional cap-binding domain in Rift Valley fever virus L protein.
    Gogrefe N; Reindl S; Günther S; Rosenthal M
    PLoS Pathog; 2019 May; 15(5):e1007829. PubMed ID: 31136637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding.
    Fechter P; Mingay L; Sharps J; Chambers A; Fodor E; Brownlee GG
    J Biol Chem; 2003 May; 278(22):20381-8. PubMed ID: 12646557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of children hospitalized with influenza A and B infections during the 2012-2013 influenza season in Italy.
    Mancinelli L; Onori M; Concato C; Sorge R; Chiavelli S; Coltella L; Raucci U; Reale A; Menichella D; Russo C
    BMC Infect Dis; 2016 Jan; 16():6. PubMed ID: 26743673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase.
    Gregor J; Radilová K; Brynda J; Fanfrlík J; Konvalinka J; Kožíšek M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33673017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Clinical Evaluation of a Novel FluA/FluB/SARS-CoV-2 Multiplex LAMP and Commercial FluA/FluB/SARS-CoV-2/RSV RT-qPCR Assays.
    Jee H; Park S; Lee J; Lim CS; Jang WS
    Diagnostics (Basel); 2023 Apr; 13(8):. PubMed ID: 37189533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two separate sequences of PB2 subunit constitute the RNA cap-binding site of influenza virus RNA polymerase.
    Honda A; Mizumoto K; Ishihama A
    Genes Cells; 1999 Aug; 4(8):475-85. PubMed ID: 10526235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of Four sample-to-answer influenza A/B and RSV nucleic acid amplification assays using adult respiratory specimens.
    Banerjee D; Kanwar N; Hassan F; Lankachandra K; Selvarangan R
    J Clin Virol; 2019 Sep; 118():9-13. PubMed ID: 31302479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and outcomes of influenza by virus type/subtype/lineage in pediatric patients.
    Han SB; Rhim JW; Kang JH; Lee KY
    Transl Pediatr; 2021 Jan; 10(1):54-63. PubMed ID: 33633937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free energy calculations and binding analysis of two potential anti- influenza drugs with Polymerase basic protein-2 (PB2).
    Lv HM; Guo XL; Gu RX; Wei DQ
    Protein Pept Lett; 2011 Oct; 18(10):1002-9. PubMed ID: 21592080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Clinical Presentations and Disease Severity of Children Hospitalized with Influenza A and B.
    Ekşi A; Öztürk GK; Çiçek C; Gülen F; Demir E
    Turk Arch Pediatr; 2024 Jul; 59(4):397-403. PubMed ID: 39140694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit.
    Ma X; Xie L; Wartchow C; Warne R; Xu Y; Rivkin A; Tully D; Shia S; Uehara K; Baldwin DM; Muiru G; Zhong W; Zaror I; Bussiere DE; Leonard VHJ
    Sci Rep; 2017 Aug; 7(1):9385. PubMed ID: 28839261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus.
    He X; Zhou J; Bartlam M; Zhang R; Ma J; Lou Z; Li X; Li J; Joachimiak A; Zeng Z; Ge R; Rao Z; Liu Y
    Nature; 2008 Aug; 454(7208):1123-6. PubMed ID: 18615018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation.
    Tian Y; Sang H; Liu M; Chen F; Huang Y; Li L; Liu S; Yang J
    Microbes Infect; 2020; 22(6-7):254-262. PubMed ID: 32554102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational polymorphism of m7GTP in crystal structure of the PB2 middle domain from human influenza A virus.
    Tsurumura T; Qiu H; Yoshida T; Tsumori Y; Hatakeyama D; Kuzuhara T; Tsuge H
    PLoS One; 2013; 8(11):e82020. PubMed ID: 24312396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two mutations in the C-terminal domain of influenza virus RNA polymerase PB2 enhance transcription by enhancing cap-1 RNA binding activity.
    Zhang S; Wang Q; Wang J; Mizumoto K; Toyoda T
    Biochim Biophys Acta; 2012 Jan; 1819(1):78-83. PubMed ID: 22146492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of Binding Affinity between Potential Antiviral Agents and PB2 Protein of Influenza A: Non-equilibrium Molecular Dynamics Simulation Approach.
    Pham T; Nguyen HL; Phan-Toai T; Nguyen H
    Int J Med Sci; 2020; 17(13):2031-2039. PubMed ID: 32788882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.